A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia (SHINE)
- Study Title
- A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
- Teva Identifier
- TV46000-CNS-30078
- ClinicalTrials.gov Identifier
- NCT03893825
- Study Status
- Completed
- Trial Condition(s)
- Schizophrenia
- Interventions
- Drug: TV-46000 | Drug: Placebo
- EudraCT Number
- 2019-000063-24
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult, Older Adult
- Age Range
- 13 Years to 65 Years
- Trial Duration
- April 17, 2019 - December 02, 2021
- Phase
- Phase 3